Proactive Investors - Run By Investors For Investors

Abcam shares tumble as outlook misses expectations despite double-digit earnings growth in full year

Despite reporting adjusted earnings growth of 20.5%, the firm saw its shares fall as its 36% margin growth forecast for the new year came in below analyst estimates
Antibodies
Even a final dividend hike to 8.58p from 7.36p wasn't enough to stop the slide

Abcam PLC (LON:ABC) saw its shares take a tumble in early trading Monday despite double-digit growth in its underlying earnings (EBITDA) for the full year after its estimates for the new financial year missed expectations.

The AIM 100 supplier of research tools to the life sciences industry reported adjusted EBITDA for the year of £88.3mln, up 20.5% on the previous year, while revenues climbed 7.4% to £233.2mln (or 10.7% on a constant currency basis).

READ: Abcam forecasts double-digit revenue growth for full-year as it sees product growth across the board

The company also upped its final dividend for the year to 8.58p from 7.36p the year before, increasing its total dividend 17.9% to 12p per share.

The double-digit growth and dividend hike weren’t enough to placate shareholders though, with the stock tumbling 23.3% to 1,137p after Abcam forecast that its adjusted EBITDA margin for the new financial year would be around 36% because of increased investment in its strategic initiatives.

Analysts at City broker Peel Hunt said that margin forecast had come in “well below” their estimates of 39% for the new financial year, while also being less than the margin reported in the results, which grew to 37.9% from 33.8% the previous year.

The broker added that the full year adjusted EBITDA of £88.3mln had come in below analyst estimates of £90.4mln for the period and expected a “significant pull-back” in the share price in response.

 

View full ABC profile View Profile

Abcam Timeline

Newswire
January 10 2017

Related Articles

test tubes
April 16 2019
Summit Therapeutics' potential breakthrough targets C.difficile
tablets and pills
Tue
Here we take a closer look at Clinigen, the specialty pharma group and AIM billionaire
dna strand
May 08 2019
The latest update reveals the company significant clinical and commercial milestones in sight

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use